AKT1 and diabetic kidney disease: Multi-bioactive compounds combination may improve DKD by regulating TGF-β/Smad and PI3K/Akt/FoxO signaling pathways and abnormal protein expression, thereby affecting the process of oxidative stress, ECM collagen deposition and kidney tissue fibrosis (Figure 7).